ALK-Abelló A/S
ALK-B
Rank in Stocks
#2340
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Share Price
$37.79
Market Cap
$8.38B
Change (1 day)
0.00%
Change (1 year)
12.73%
Country
DK
Trade ALK-Abelló A/S (ALK-B)
Category
Healthcare
P/S ratio for ALK-Abelló A/S (ALK-B)
P/S ratio as of October 2026 TTM: 7.33
According to ALK-Abelló A/S latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.33. At the end of 2023 the company had a P/S ratio of 4.64.
P/S ratio history for ALK-Abelló A/S from 2004 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.33 | 15.30% |
| 2024 | 6.36 | 37.07% |
| 2023 | 4.64 | -1.19% |
| 2022 | 4.70 | -51.14% |
| 2021 | 9.61 | 22.91% |
| 2020 | 7.82 | 43.61% |
| 2019 | 5.44 | 44.87% |
| 2018 | 3.76 | 47.54% |
| 2017 | 2.55 | -15.26% |
| 2016 | 3.01 | -9.18% |
| 2015 | 3.31 | 28.03% |
| 2014 | 2.58 | -2.21% |
| 2013 | 2.64 | 62.00% |
| 2012 | 1.63 | 20.58% |
| 2011 | 1.35 | -8.35% |
| 2010 | 1.48 | -29.77% |
| 2009 | 2.10 | -27.84% |
| 2008 | 2.91 | -25.47% |
| 2007 | 3.91 | -24.68% |
| 2006 | 5.19 | -33.94% |
| 2005 | 7.86 | 751.69% |
| 2004 | 0.92 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | 36.67% |
US
|
|
| 40.55 | 452.98% |
US
|
|
| 3.96 | -45.98% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 38.36% |
NL
|
